新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Abbott血糖测试仪FreeStyle Precision Pro获FDA批准上市

Abbott血糖测试仪FreeStyle Precision Pro获FDA批准上市

来源:生物谷 2013-07-26 23:39

2013年7月26日讯 /生物谷BIOON/ --Abbott Laboratories生产的测定血糖仪器FreeStyle Precision Pro已经获得FDA批准允许上市。这款血糖仪能够实时监测患者血糖浓度并防止不同患者间的交叉影响,同时所测得的数据能够无线传输给医生以供治疗分析用。Abbott公司表示,FreeStyle Precision Pro的上市表明Abbott公司的医疗器械研发实力又进一步。(生物谷Bioon.com)

详细英文报道:

Abbott Laboratories ($ABT) picked up FDA clearance to market the FreeStyle Precision Pro, an inpatient blood glucose monitor the company said can stream test results in real time.

The device keeps tabs on blood sugar and beta-ketone levels at hospital bedsides, and it's the only technology of its kind to use individually foil-wrapped test strips, drastically cutting the risk of cross-contamination, Abbott said. The device is outfitted with wireless connectivity, sending test data straight from a handheld monitor to hospital staff.

"The FreeStyle Precision Pro system represents a significant step forward as we work to provide tools to improve the way hospitals manage patients' glucose levels," Abbott Diabetes Care Senior Vice President Heather Mason said in a statement.

And any step forward would be a benefit for Abbott's slumping medical device business. Last quarter, the company's diabetes device revenue slid 1.3% to $326 million, dragged down by pricing and reimbursement pressures in the U.S. However, Abbott has seen a strong uptick for its FreeStyle InsuLinx meter in emerging markets, the company said, and it's still doing well with hospital-based technologies like the FreeStyle Precision Pro.

But diabetes tech wasn't the biggest contributor to Abbott's 1.6% Q2 slump in medical devices. The company's vascular business is still enduring a decline in demand for stents, dropping 2% to $750 million on the quarter. Medical optics, which includes intraocular lenses and eye surgery devices, fell 1.2% to $280 million.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库